Analyst Price Targets — CLDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 10:58 am | — | Barclays | $24.00 | $26.68 | TheFly | Celldex price target raised to $24 from $21 at Barclays |
| November 11, 2025 10:24 am | — | Barclays | $21.00 | $22.67 | TheFly | Celldex price target lowered to $21 from $25 at Barclays |
| October 13, 2025 9:27 am | — | Barclays | $25.00 | $26.77 | TheFly | Celldex initiated with an Underweight at Barclays |
| March 20, 2025 7:51 am | — | Morgan Stanley | $46.00 | $19.88 | TheFly | Celldex initiated with an Overweight at Morgan Stanley |
| October 29, 2024 7:25 am | Joseph Pantginis | H.C. Wainwright | $80.00 | $27.12 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX) |
| September 25, 2024 3:10 pm | Derek Archila | Wells Fargo | $44.00 | $36.02 | TheFly | Celldex upgraded to Overweight from Equal Weight at Wells Fargo |
| June 17, 2024 4:15 pm | Alex Thompson | Stifel Nicolaus | $58.00 | $34.91 | TheFly | Celldex initiated with a Buy at Stifel |
| November 10, 2023 5:05 am | Derek Archila | Wells Fargo | $27.00 | $25.78 | StreetInsider | Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight |
| November 11, 2022 8:51 am | — | Guggenheim | $63.00 | $39.89 | Benzinga | Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63 |
Latest News for CLDX
- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N. J. , March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in…
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 - HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2…
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update.
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company's global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy…
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company's Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLDX.
U.S. House Trading
No House trades found for CLDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.